About Tumor necrosis factor receptor superfamily member 13B
Tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) is a protein
from Homo sapiens identified by UniProt accession
O14836, 293 residues long.
MolForge cross-references it against 0 known binders and
477 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 13B |
|---|
| UniProt accession | O14836 |
|---|
| Gene | TNFRSF13B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 293 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (477)
Diseases linked to this target (Open Targets).
- immunodeficiency, common variable, 2 · score 0.79
- total blood protein measurement · score 0.67
- inborn error of immunity · score 0.66
- platelet crit · score 0.65
- common variable immunodeficiency · score 0.65
- monocyte count · score 0.63
- platelet count · score 0.63
- erythrocyte count · score 0.62
- lymphocyte count · score 0.62
- serum albumin measurement · score 0.62
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O14836-F1 | alphafold | PREDICTED | 62.46 | — |
Amino-acid sequence (293 residues)
MSGLGRSRRG GRSRVDQEER FPQGLWTGVA MRSCPEEQYW DPLLGTCMSC KTICNHQSQR TCAAFCRSLS CRKEQGKFYD HLLRDCISCA SICGQHPKQC AYFCENKLRS PVNLPPELRR QRSGEVENNS DNSGRYQGLE HRGSEASPAL PGLKLSADQV ALVYSTLGLC LCAVLCCFLV AVACFLKKRG DPCSCQPRSR PRQSPAKSSQ DHAMEAGSPV STSPEPVETC SFCFPECRAP TQESAVTPGT PDPTCAGRWG CHTRTTVLQP CPHIPDSGLG IVCVPAQEGG PGA
Explore Tumor necrosis factor receptor superfamily member 13B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets